CBmed, based in Graz, Austria, is a public-private partnership focused on biomarkers. With a network of over 50 international partners from industry and academia across four continents, CBmed is dedicated to advancing biomarker research through global collaboration.

Founded in 2014, CBmed is a clinical and biomedical research center dedicated to advancing translational medicine. By seamlessly connecting scientific discoveries with patient care, we integrate world-class research infrastructure, scientific expertise, medical knowledge, and strategic partnerships with industry leaders both nationally and ...

Notre équipe expérimentée de professionnels médicaux et para-médicaux est là pour vous accompagner dans une prise en charge optimal des problèmes cardio-vasculaire. Découvrez nos services et prenez rendez-vous dès aujourd’hui pour une prise en charge complète et …

At CBmed, we drive innovation in precision medicine, working on projects that push the boundaries of scientific research. By joining our team, you’ll collaborate with top experts, take on exciting challenges, and play a key role in advancing personalized medicine. We offer an inclusive environment that values creativity, growth, and teamwork.

2024年2月20日 · CBmed 是转化医学研究的先锋者。通过与格拉茨医科大学和维也纳医科大学紧密合作，该公司在科学发现与患者治疗之间架起了一座桥梁。CBmed 建立了一个独特的多组学技术平台，以加速新型生物标记物的发现。

2024年2月20日 · 近日，勃林格殷格翰和CBmed 医学生物标志物研究中心（CBmed）宣布建立长期战略合作伙伴关系。 该合作将应用转化医学方法加快开发同类首创药物，从而改变肿瘤患者的生活，以实现勃林格的最终目标，治愈一系列肿瘤疾病。

CBmed research projects will identify new biomarkers, validate potential biomarkers and conduct translational biomarker research for products to be used in clinical practice. CBmed will develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.

2024年2月6日 · 近日，勃林格殷格翰和CBmed 医学生物标志物研究中心（CBmed）宣布建立长期战略合作伙伴关系。 该合作将应用转化医学方法加快开发同类首创药物，从而改变肿瘤患者的生活，以实现勃林格的最终目标，治愈一系列肿瘤疾病。

2024年2月8日 · The partnership with CBmed will enable Boehringer Ingelheim to identify and validate biomarkers for projects across its growing cancer pipeline to support early proof of therapeutic effect, identification of new indications and patient selection. This will accelerate and broaden Boehringer Ingelheim’s oncology portfolio.

CBmed, based in Graz, Austria, is a public-private partnership focused on biomarkers. With a network of over 50 international partners from industry and academia across four continents, CBmed is dedicated to advancing biomarker research through global collaboration.